3-溴吡嗪-2-甲腈 | 1250022-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-溴吡嗪-2-甲腈
• 英文名称: 3-bromopyrazine-2-carbonitrile
• CAS: 1250022-24-2
• 化学式: C₅H₂BrN₃
• mdl: MFCD16842970
• 分子量: 183.995
• InChiKey: NAPIQNUAYLKBHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二氟溴乙酸乙酯 、 3-溴吡嗪-2-甲腈 在 铜 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 以41%的产率得到ethyl (3-cyanopyrazin-2-yl)difluoroacetate
  参考文献：
  名称：

  Synthesis of gem-difluorinated 1,6-naphthyridine-5,7-diones

  摘要：

  A synthetic route toward new 8,8-difluoro-1,6-naphthyridine-5,7-diones, which are of interest as new building blocks in pharmaceutical chemistry, is described. The key steps include a copper-mediated cross-coupling of ethyl bromodifluoroacetate and 2-bromo-3-cyanopyridine, followed by hydrolysis of the nitrile function and subsequent cyclization. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.05.122
• 作为产物：
  描述：

  2-氯-3-氰基吡嗪 在 三甲基溴硅烷 作用下， 以 丙腈 为溶剂， 反应 16.0h， 以79%的产率得到3-溴吡嗪-2-甲腈
  参考文献：
  名称：

  Synthesis of gem-difluorinated 1,6-naphthyridine-5,7-diones

  摘要：

  A synthetic route toward new 8,8-difluoro-1,6-naphthyridine-5,7-diones, which are of interest as new building blocks in pharmaceutical chemistry, is described. The key steps include a copper-mediated cross-coupling of ethyl bromodifluoroacetate and 2-bromo-3-cyanopyridine, followed by hydrolysis of the nitrile function and subsequent cyclization. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.05.122

文献信息

• [EN] DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS D'AMIDINE À DIAZINE FUSIONNÉE UTILISÉS EN TANT QU'INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2016044120A1

  公开（公告）日：2016-03-24

  In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I) or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1A, R1B, R2, RA, ring A, RA, m, L1, RL, ring C, RC, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些C-6螺环碳杂环亚胺噻二嗪化合物，包括化合物式（I）或其互变异构体，以及所述化合物和所述互变异构体的药学上可接受的盐，其中R1A、R1B、R2、RA、环A、RA、m、L1、RL、环C、RC和p如本文所定义。本发明的新化合物可用作BACE抑制剂和/或用于治疗和预防与之相关的各种病理。还公开了包括一种或多种此类化合物（单独和与一种或多种其他活性剂的组合）的药物组合物，以及其制备和使用方法，包括可能用于治疗阿尔茨海默病的方法。
• Pyranodipyridine Compound
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20170137436A1

  公开（公告）日：2017-05-18

  Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:

  由化学式(I)到(XXII)表示的化合物或其药用可接受的盐：
• Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
  申请人：Cancer Research Technology Limited

  公开号：US08058045B2

  公开（公告）日：2011-11-15

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation, wherein: —X═ is independently —CRA5═ or —N═; and the rest of the substituents are as specified in the claims.

  本发明涉及治疗化合物领域，更具体地涉及某些双芳基胺化合物（以下简称BAA化合物），特别是公式（I）中的某些吡嗪-2-基吡啶-2-基胺和吡嗪-2-基嘧啶-4-基胺化合物，其中，除其他作用外，抑制检查点激酶1（CHK1）的激酶功能。本发明还涉及包含这些化合物的制药组合物，并且在体内外使用这些化合物和组合物来抑制CHK1激酶功能，并治疗由CHK1介导的疾病和病况，这些病况通过抑制CHK1激酶功能得到改善等，包括增殖性疾病如癌症等，可选地与另一种制剂联合使用，例如（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向剂；和（e）电离辐射，其中：—X═独立地为—CRA5═或—N═；其余取代基如权利要求中所述。
• Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use
  申请人：Collins Ian

  公开号：US20120040967A1

  公开（公告）日：2012-02-16

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明涉及治疗化合物领域，更具体地涉及某些双芳基胺化合物（以下称为BAA化合物），尤其是某些吡嗪-2-基吡啶-2-基胺和吡嗪-2-基嘧啶-4-基胺化合物，它们可以抑制检查点激酶1（CHK1）激酶的功能。本发明还涉及包含这些化合物的药物组合物，以及在体内外使用这些化合物和组合物来抑制CHK1激酶的功能，并在治疗由CHK1介导的疾病和病况，通过抑制CHK1激酶的功能得到改善的疾病和病况，包括增殖性疾病如癌症等，可选择与另一种药物联合使用，例如（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向药物；和（e）电离辐射。
• [EN] MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE<br/>[FR] MODULATEURS DE TRPML, LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：[en]CARAWAY THERAPEUTICS, INC.

  公开号：WO2023055920A1

  公开（公告）日：2023-04-06

  The present disclosure relates to pharmaceutical compounds of the Formula (I), (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders, the modulators including compounds of the Formula (I), (Ia), (Ib), or (Ic). Such methods of use include treatment of ciliopathies.